| |
Physicians need to clearly understand the benefits and limitations of cholesterol-lowering therapies
and realize that, while statins have dramatically improved outcomes for those with dyslipidemia, there
is still a need for improved risk reduction for patients in all risk categories. Extensive clinical trial data
have shown aggressive LDL lowering to provide considerable CVD risk reduction, particularly in high-risk
patients. Existing combination treatments and future therapies with new targets in lipid metabolism may allow
for both improved LDL reduction and improved overall lipoprotein profiles. A thorough understanding of lipid
metabolism and the mechanisms of lipid-lowering therapies will provide a rationale for combining compatible
drugs for greater LDL reduction.
|
| |
|
 |
 |
 |
 |
MODERATOR:
Lori Mosca, MD
Associate Professor of Medicine
Columbia University College of Physicians and Surgeons
Director, Preventive Cardiology, New York-Presbyterian Hospital
Director, Columbia Center for Heart Disease Prevention, New York, NY |
|
| |
|
|
|
| |
|
Faculty: |
|
| |
 |
Michael H. Davidson, MD, FACC, FACP
Executive Medical Director, Radiant Research
Director, Preventive Cardiology Center
Professor of Medicine, Rush University Medical Center, Chicago, IL |
|
| |
|
|
|
| |
 |
Sergio Fazio, MD, PhD
Professor of Medicine and Pathology, Co-Director, Atherosclerosis Research Unit
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN |
|
| |
|
|
|
| |
 |
Peter Ganz, MD, FACC
Associate Professor of Medicine, Harvard Medical School
Director of Research, Cardiac Catheterization Laboratory
Brigham and Women’s Hospital, Boston, MA |
|
| |
|
|
|
| |
 |
Antonio M. Gotto Jr., MD, DPhil
Stephen and Suzanne Weiss Dean
Professor of Medicine, Weill Cornell Medical College, New York, NY |
|
| |
|
| |
LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Identify the LDL-C goals for moderate- and high-risk patients
- Detail the percentage of patients reaching LDL goal on statin therapy
- List two mechanisms of cholesterol synthesis and absorption
- Describe the safety and efficacy of combination therapy in dyslipidemia
- Identify patients who might benefit from combination lipid-lowering therapy
- List two or more clinical trials which provide a rationale for maximizing medical therapy in high-risk dyslipidemic patients
TARGET AUDIENCE
This activity is intended for cardiologists and other health care professionals attending the AHA 2007 Annual Meeting.
ACCREDITATION
 The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
|
CME CREDIT
The Potomac Center for Medical Education designates this educational activity for a
maximum of 2 AMA PRA Category I credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE
Potomac Center for Medical Education (PCME) adheres to the guidelines of the
Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits
are awarded must be balanced, independent, objective, and scientifically rigorous.
All faculty in a position to control the content of a continuing medical education
program sponsored by the Potomac Center for Medical Education are required to
disclose any relevant financial relationships with any commercial interest. All conflicts
are identified and resolved by PCME in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure
objectivity and that the activity is free of commercial bias.
SPECIAL SERVICES
 Event staff will be glad to assist you with any special needs (e.g. physical, dietary, etc.).
|
|
| |
|
|
|
| |
|
| |
|
|
|
|
